RE:CD8+ TiLs and T-cell exhaustionWith the exception of PD-L1 and TMB, there are no predictive biomarkers to guide immune checkpoint inhibitor treatment decisions in advanced or metastatic breast cancer, according to a paper that was pressented at ESMO 2024. This may have been the case UP UNTIL NOW with clinical evidence that shows ONCY's pelareorep is able to drive biomarkers that enhance exisiting and new CD8+ -TiLs complex T cells in the blood and TME in advance of immune checkpoint inhibition.
This data will appear in an ASCO 2024 poster presention given by ONCY and entitled: Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-presentations-at-the-american-society-of-clinical-oncology-annual-meeting/
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00414-4/fulltext
https://www.esmoopen.com/article/S2059-7029(24)00732-4/fulltext